AUSTIN, TX – Tekton Research, a clinical research company focusing on clinical trials for pharmaceuticals and device companies, is excited to announce the appointment of Bruce Wakeman as Chief Commercial Officer. With a distinguished career spanning the pharmaceutical and clinical research industries, Bruce brings a wealth of experience and a deep commitment to advancing patient-centric solutions.
In his role as Chief Commercial Officer, Bruce Wakeman will leverage his extensive background to spearhead Tekton’s commercial strategy and drive revenue growth. His expertise in forging strategic partnerships and his passion for collaboration will be instrumental in expanding Tekton’s presence in the healthcare landscape.
Bruce holds a Bachelor of Science degree in Business Management from the University of North Carolina, Wilmington.
Prior to joining Tekton Research, Bruce served as Chief Commercial Officer at Emvenio Research, where he played a pivotal role in shaping the company’s growth trajectory. Before that, he held senior leadership positions at Matrix Medical Network and Inteliquet, where he demonstrated a keen ability to drive revenue growth and foster innovation.
“We are delighted to welcome Bruce Wakeman to the Tekton Research team,” said Kip McKenzie, CEO of Tekton Research. “His track record of success and his commitment to driving innovation make him the ideal leader to drive our commercial strategy forward.”
Bruce Wakeman’s appointment signifies Tekton Research’s continued dedication to revolutionizing the clinical research landscape and delivering impactful solutions for participants, sponsors, and communities alike.
For more information or to request a meeting, contact [email protected].
